MedPath

study the effect of dexmedetomidine drug in preventing confusional state and agitation that occurs in patients undergoing brain surgery under general anaesthesia.

Not yet recruiting
Conditions
Other intraoperative and postprocedural complications and disorders of nervous system,
Registration Number
CTRI/2021/11/037735
Lead Sponsor
Institutional Review BoardChristian Medical CollegeVellore
Brief Summary

Emergenceagitationand delirium are well-described phenomena during emergence from generalanaesthesia, especially in the paediatric population.

EmergenceAgitation (EA) is an “unpleasant state of extreme arousal†characterized bynon-purposeful movement, restlessness, thrashing, incoherence, inconsolability,and unresponsiveness usually following emergence from General Anaesthesia. Thetrue incidence of EA in children is unclear but has been estimated to bebetween 10 - 80 %.

EmergenceDelirium (ED)  is an altered state ofconsciousness, which begins with emergence from anesthesia and continuesthroughout the early recovery period. ED is a disturbance of awareness of, orattention to, the child’s environment, and manifests as disorientation,hyperactive/hypoactive behavior, and hypersensitivity in the immediate periodafter anesthesia.

Althoughthere is significant ongoing research on the incidence, risk factors, and theprobable consequences of EA/ED, neurosurgical procedures have generally beenexempt owing to the complexity in differentiation between the neurologicalconditions and the effect of recovery from anaesthetics.  A study done in the adult neurosurgical populationhas shown a higher incidence of EA in neurosurgical patients (29%).

Childrenundergoing craniotomy are more vulnerable to the stress that follows EA/ED. Ina recent observational study done in our institution, the incidence of emergenceagitation was 28% in the paediatric population undergoing craniotomy.

Total intravenousanaesthetic (TIVA) techniques with propofol, which has been the mainstay of neurosurgicalpractice have been associated with a reduced incidence of EA/ED in othersurgical procedures. However, in children, it is often necessary to use highconcentration volatile anaesthetics to induce general anaesthesia beforeinitiation of TIVA as they may not cooperate for intravenous access whichpredisposes them to develop EA/ED.

Dexmedetomidineis a selective alpha-2 receptor agonist acting on alpha-2receptors in the locus ceruleous of the pons. Recently, Dexmedetomidine isbeneficial in reducing the incidence of EA/ED in children undergoing generalanaesthesia. However, there is no literature regarding its use in thepaediatric neurosurgical population.

We hypothesizethat the use of intravenous dexmedetomidine as an infusion at a dose of0.5mcg/kg/hr could reduce the incidence of EA/ED in paediatric patientsundergoing craniotomy.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

ASA 1 and 2 Paediatric age group patients planned for craniotomy under general anaesthesia will be recruited for the study.

Exclusion Criteria
  • 1)ASA 3 and above.
  • 2)Known allergy to study drugs.
  • 3)History of renal disease-age appropriate e-GFR criteria 4)History of liver disease.
  • 5)Psychiatric illness 6)Heart block, known case of seizure disorder coming for seizure surgery 7)Patient refusal 8)GCS <15.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Emergence Delirium as assessed by the PAED scale7 time points,T1-at recovery,T2 after 2 hours of recovery,T3-6 hours,T4-12 hours,T5-24 hours,T6- 36 hours,T7-48 hours
Secondary Outcome Measures
NameTimeMethod
1)Emergence Agitation as assessed by Watcha, Richmond’s agitation sedation scale2.Intraoperative and Postoperative haemodynamics

Trial Locations

Locations (1)

Christian Medical College

🇮🇳

Vellore, TAMIL NADU, India

Christian Medical College
🇮🇳Vellore, TAMIL NADU, India
DrAjisheen Borgeo
Principal investigator
9995927960
sheenborgeo@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.